Alfred Sandrock - 02 Apr 2026 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Reporting relationship: President and CEO, Director
Issuer ticker: VYGR
Reported as of: 02 Apr 2026
Net transaction value: -$44,548
SEC form: 4
Accepted by SEC: 03 Apr 2026, 17:55:27 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Alfred Sandrock

Key filing fact

Alfred Sandrock filed Form 4 for Voyager Therapeutics, Inc. (VYGR) on 03 Apr 2026.

Key facts

This page summarizes Alfred Sandrock's Form 4 filing for Voyager Therapeutics, Inc. (VYGR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Apr 2026, 17:55.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$44,548.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001577061 Primary reporting owner

Sandrock Alfred

Relationship: President and CEO, Director
Address: C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON
Signature: /s/ Gregory L. Shiferman, as Attorney-in-Fact for Alfred Sandrock
Signature date: 03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYGR transaction

Common Stock

Sale

Transaction value: $44,548
Shares: -11,511
Change %: -2.4%
Price: $3.87
Shares after: 472,549
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.